Entity

Time filter

Source Type


Vidal M.,Servei dEndocrinologia i Nutricio
Revista de enfermería (Barcelona, Spain) | Year: 2013

The possibility of obtaining a continuous reading of glucose may represent a breakthrough and a useful tool for the management of diabetes. Technological advances can improve the quality of life and people with diabetes metabolic control, even if this means having to learn and incorporate new technical concepts, new algorithms for pattern modification and new challenges in Therapeutic Education. Source


Corcoy R.,Servei dEndocrinologia i Nutricio
Revista de enfermería (Barcelona, Spain) | Year: 2011

The usual scenario of treatment of pregnant women with diabetes, either gestational or pregestational is the coincidence of: 1) the difficulty that entails changing insulin sensitivity, 2) the importance of glycemic control that resembles as much as possible to that of healthy pregnant women, and 3) the willingness of the mother The latter circumstance makes it common that patients with type 1 diabetes and poor glycemic control have impeccable glycemic records during pregnancy and that women with gestational diabetes and unhealthy eating patterns, change them substantially during pregnancy. But the first two assumptions imply a major difficulty Source


Garcia-Patterson A.,Servei dEndocrinologia i Nutricio | Aulinas A.,Servei dEndocrinologia i Nutricio | Sojo L.,Servei dEndocrinologia i Nutricio | Ginovart G.,Servei de Pediatria | And 3 more authors.
Diabetic Medicine | Year: 2011

Aims To assess perinatal outcome in women with pregestational diabetes mellitus according to the sex of the fetus. Methods A retrospective review of all singleton pregnancies of women with pregestational diabetes progressing to a gestational age of 22weeks or more who attended the diabetes and pregnancy clinic from 1981 to 2006 (n=455). We compared maternal characteristics and perinatal outcomes (perinatal mortality, major congenital malformations, small and large for gestational age newborns, preterm birth and a composite of the former) according to the sex of the fetus. A logistic regression analysis was performed using the composite perinatal outcome as the dependent variable and all maternal variables and sex of fetus as potential predictors. Results Maternal characteristics did not differ in mothers of male and female newborns. In the whole cohort, the composite perinatal outcome was significantly higher in male fetuses; adjusted OR 1.61 (95%CI1.04-2.50). Conclusions In women with pregestational diabetes, perinatal outcome was poorer in male newborns despite similar maternal characteristics. © 2011 The Authors. Diabetic Medicine © 2011 Diabetes UK. Source


Garcia-Patterson A.,Servei dEndocrinologia i Nutricio | Aulinas A.,Servei dEndocrinologia i Nutricio | Maria M.A.,Servei dEndocrinologia i Nutricio | Ubeda J.,Servei dEndocrinologia i Nutricio | And 10 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2012

Context: In diabetic pregnancy, neonatal hypoglycemia (NH) is usually attributed to insufficient regulation of maternal glycemic control. Recent data suggest that maternal body mass index (BMI) could have an influence. Objective: Our objective was to determine whether an association exists between maternal prepregnancy BMI category and occurrence of NH among infants born to women with gestational diabetes mellitus (GDM). Design and Setting: This was a retrospective study including all GDM pregnancies delivered between 1986 and 2006 at a tertiary care center (Hospital de la Santa Creu i Sant Pau, Barcelona). Patients and Outcomes: GDM was diagnosed using universal screening and National Diabetes Data Group criteria. Two thousand ninety-two newborns (1925 singletons, 85% of total GDM offspring) were studied. NH was defined according to Cornblath criteria. In addition to maternal BMI, we considered other variables such as glucose values at diagnosis or third-trimester glycated hemoglobin as potential predictors of NH. We explored whether the association between maternal BMI and NH could be due to intermediate steps such as cesarean section or abnormal birth weight. Results: The rate of NH was 3%. In the bivariate analysis, prepregnancy BMI was higher in the NH group (24.45 vs. 23.19 kg/m2, P < 0.02). In the logistic regression analysis, prepregnancy BMI of at least 25 kg/m2 was independently associated with NH whetherthe analysis included intermediate variables (odds ratio = 2.11; 95% confidence interval = 1.10-4.03) or not (odds ratio = 2.66; 95% confidence interval = 1.44-4.92). Conclusions: Pregestational BMI should be considered among the predictors of NH in offspring of women with GDM. Copyright © 2012 by The Endocrine Society. Source


Auguet T.,Rovira i Virgili University | Auguet T.,Hospital Universitari Joan Tarragona | Terra X.,Rovira i Virgili University | Porras J.A.,Hospital Universitari Joan Tarragona | And 9 more authors.
Clinical Biochemistry | Year: 2013

Objectives: The few studies on the physiopathological role of visfatin in morbid obesity and the related metabolic diseases have led us to examine visfatin levels and its liver gene expression in morbidly obese women with non-alcoholic fatty liver disease (NAFLD). Design and methods: We examined the circulating levels of visfatin by ELISA in serum samples from 95 morbidly obese women (MO) (BMI>40kg/m2) who underwent bariatric surgery and 38 normal weight control women (BMI<25kg/m2). We analysed visfatin liver and adipose tissue mRNA expression by RT-PCR. We evaluated the circulating levels and gene expression of adiponectin, resistin, RBP4, TNFα, IL6 and CRP. Results: Serum visfatin was significantly higher in MO compared with controls, and also in MO with NAFLD was significantly higher than MO with normal liver. We found that NAFLD diabetic patients presented similar serum visfatin levels than non-diabetic. Serum visfatin correlated with IL6 (r = 0.496; p<0.001) and CRP levels (r = 0.241; p = 0.049).Liver visfatin expression was significantly higher in MO compared to controls and was also significantly higher in MO with NAFLD than in MO with normal liver. Visfatin liver expression correlated positively with resistin (r = 0.436, p = 0.018) and TNFα expression (r = 0.328, p = 0.028).Visfatin expression in adipose tissues was similar among the MO groups analysed. Conclusion: Serum visfatin and its liver expression are higher in MO women with NAFLD, irrespective of the presence of diabetes. Serum visfatin and its liver expression correlate positively with pro-inflammatory factors. These findings suggest that visfatin may be a molecule related with fat inflammation in morbid obesity and fatty liver disease. © 2012 The Canadian Society of Clinical Chemists. Source

Discover hidden collaborations